Clayton Chan, MD
Medical Oncology · Honolulu, HINPI 1346340239
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.6% of the total across 65 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $987 and has fallen 62.0% since, to $375 in 2025.
Across 65 payments — averaging $28.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$292
- Pfizer$254
- Novartis$153
- Blueprint Medicines Corporation$122
- AbbVie$109
- Neurocrine Biosciences, Inc.$104
- plus $832 from 22 others
What the payments were for
- Food & beverage$1,76695%
- Education$1005%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 8 | $292 |
| Pfizer | 7 | $254 |
| Novartis | 8 | $153 |
| Blueprint Medicines Corporation | 1 | $122 |
| AbbVie | 5 | $109 |
| Neurocrine Biosciences, Inc. | 4 | $104 |
| AVEO Pharmaceuticals, Inc. | 1 | $100 |
| Coherus Oncology, Inc. | 3 | $85 |
| Regeneron Healthcare Solutions, Inc. | 2 | $66 |
| Lilly USA, LLC | 3 | $56 |
| Daiichi Sankyo Inc. | 2 | $52 |
| Incyte Corporation | 2 | $50 |
| Jazz Pharmaceuticals Inc. | 1 | $39 |
| Beigene USA, Inc. | 2 | $37 |
| Astellas Pharma US Inc | 2 | $34 |
| Genentech USA, Inc. | 2 | $33 |
| EUSA Pharma (US) LLC | 1 | $31 |
| Boehringer Ingelheim | 1 | $29 |
| ADC Therapeutics America, Inc. | 1 | $28 |
| Eisai Inc. | 1 | $27 |
| Novo Nordisk | 1 | $25 |
| Karyopharm Therapeutics Inc. | 1 | $25 |
| Taiho Oncology, Inc. | 1 | $25 |
| Caris MPI, Inc. | 1 | $24 |
| Exelixis Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Gilead | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XTANDI$121
How this compares
Too few medical oncology providers in Hawaiito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 14 | $672 |
| Letrozole | 11 | $283 |
| Ondansetron OdtOndansetron | 27 | $230 |
| Prochlorperazine Maleate | 22 | $152 |
| Prednisone | 30 | $133 |
| Dexamethasone | 15 | $43 |
| Levothyroxine Sodium | 14 | $16 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Honolulu
- Naoto UenoHonolulu$288K
- Jami FukuiHonolulu$17K
- Shaun DoneganHonolulu$17K
- Clayton ChongHonolulu$2K
- Charles MillerHonolulu$326
- Reuben GuerreroHonolulu$35
- Kevin LohHonolulu$31
- Kitty VictoriaKealakekua$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.